Security key
87184Q206
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS)
CUSIP: 87184Q206
Q4 2023 13F Holders as of 31 Dec 2023
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Total 13F shares
- 17,756,706
- Total 13F value
- $138,325,248
- Share change
- +6,919,524
- Put/Call ratio
- 1.3%
- SEC-reported price per share
- $7.79
- Number of holders
- 57
- Value change
- +$53,999,700
- Number of buys
- 31
- Number of sells
- 12
- Shares outstanding
- 27,196,692
Holder snapshot
7 signals
Show 1 more signal
Security identity
1 source field
Report period
Q4 2023
Institutions
57
Top holders
10
SYRS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2024
Previous quarter: Q3 2023
Syros Pharmaceuticals, Inc. SEC filings
Syros Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 87184Q206
Recent filing periods:
Ownership snapshot
Top reported holders of SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Bain Capital Life Science...
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
30 Sep 2023
13F
Lead comparable stake: 7.8%
Showing 1-6 of 15 holder rows.
Quick read
Bain Capital Life Sciences Investors, LLC leads the comparable SEC ownership view at 7.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
Bain Capital Life Sciences Invest...
7.8%
Avidity Partners Management LP
5.8%
Artal Group S.A.
5.4%
CHI Advisors LLC
4.8%
Flagship Pioneering, LLC
3.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
7.8%
|
$8,392,541
2,124,694 shares
|
— | 30 Sep 2023 |
| Avidity Partners Management LP |
13F
Company
|
5.8%
|
$6,245,511
1,581,142 shares
|
— | 30 Sep 2023 |
| Artal Group S.A. |
13F
Company
|
5.4%
|
$5,829,000
1,475,744 shares
|
— | 30 Sep 2023 |
| CHI Advisors LLC |
13F
Company
|
4.8%
|
$5,119,170
1,299,359 shares
|
— | 30 Sep 2023 |
| Flagship Pioneering, LLC |
13F
Company
|
3.7%
|
$3,925,700
993,848 shares
|
— | 30 Sep 2023 |
| Samsara BioCapital, LLC |
13F
Company
|
3.2%
|
$3,481,728
881,450 shares
|
— | 30 Sep 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
57
Shares
17,756,706
Rows available
57
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2023 vs Q3 2023 Across Filers
Q3 2023 holders
47
Q4 2023 holders
57
Holder diff
10
| Investor | Q3 2023 Shares | Q4 2023 Shares | Share Diff | Share Chg % | Q3 2023 value | Q4 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend